Could NDC-1308 be a new hope for secondary progressive MS?

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Could NDC-1308 be a new hope for secondary progressive MS?

Postby MSUK » Wed Nov 19, 2014 2:27 am

ENDECE Neural announced the presentation of new, pre-clinical evidence that the company’s lead compound, NDC-1308, induces remyelination and increases forelimb grip strength in a validated animal model of demyelination. As presented in a poster session at the 2014 annual meeting of the Society for Neuroscience in Washington, D.C., the improvements with NDC-1308 therapy are linked to the drug’s unique ability to repair the myelin sheath of demyelinated axons (nerve fibres).

The data, presented by Steven H. Nye, Ph.D., Vice President of Discovery at ENDECE Neural, suggest that the remyelinating properties of NDC-1308 may benefit patients with secondary progressive multiple sclerosis (SPMS). ENDECE Neural has announced plans to initiate non-clinical investigational new drug (IND)-enabling studies of NDC-1308 and a first-in-humans Phase 1 clinical trial in 2015....... Read More - http://www.ms-uk.org/emergingtherapies
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service